PHIO Profile
Phio Pharmaceuticals Corp., headquartered in Marlborough, Massachusetts, is a clinical-stage biopharmaceutical company specializing in immuno-oncology therapeutics. Established in 2011 and rebranded from RXi Pharmaceuticals Corporation to its current name in November 2018, Phio Pharmaceuticals is at the forefront of developing innovative treatments aimed at harnessing the immune system to target and eliminate cancer cells. The company’s primary focus is on utilizing its proprietary INTASYL therapeutic platform to enhance the effectiveness of immunotherapy.
The INTASYL platform is designed to modulate immune responses by regulating genes associated with immune system function. Phio Pharmaceuticals is advancing several promising product candidates through this platform. Among them is PH-762, which aims to boost the immune system’s ability to recognize and destroy cancer cells by downregulating the checkpoint protein PD-1. This approach is intended to improve the efficacy of adoptive cell transfer (ACT) therapies. Another key candidate, PH-894, targets the epigenetic protein BRD4, a critical regulator of gene expression, to enhance ACT therapies. Additionally, PH-804 focuses on inhibiting the checkpoint protein TIGIT, present on T cells and natural killer cells, to further enhance the immune response against tumors.
Phio Pharmaceuticals has established collaborations with AgonOx Inc. to advance the clinical development of novel T cell-based cancer immunotherapies. These partnerships aim to leverage the company’s INTASYL technology in combination with AgonOx’s expertise in developing innovative immunotherapies, potentially leading to new treatment options for patients with various types of cancer.
With a commitment to addressing the challenges of cancer treatment through cutting-edge science and technology, Phio Pharmaceuticals is dedicated to transforming the landscape of immuno-oncology. By focusing on targeted gene regulation and immune modulation, the company seeks to develop effective therapies that offer new hope for patients battling cancer, ultimately contributing to advancements in personalized medicine and immunotherapy.
|
